회사 개요
IQVIA Holdings Inc. is a leading global provider of clinical research services, commercial insights, and healthcare intelligence that serves the life sciences and healthcare sectors across the Americas, Europe, Africa, and the Asia-Pacific regions. The company operates within the Healthcare sector, specifically the Diagnostics & Research industry, where it leverages advanced technology to facilitate drug development and market analysis for major pharmaceutical and biotechnology clients. This massive enterprise employs approximately 93,000 individuals worldwide, reflecting its significant operational footprint and complex organizational structure required to deliver such comprehensive services. With a market capitalization of $28.68 billion and annual revenue reaching $16.31 billion, the firm demonstrates substantial scale that positions it as a dominant force in the healthcare data and research ecosystem. These valuation and revenue figures indicate that the market assigns a high premium to the company's established infrastructure, suggesting that its position as a primary vendor for clinical trials and analytics provides a stable foundation for long-term operations despite the cyclical nature of the pharmaceutical industry.
재무 건전성
The company reported total revenue of $16.31 billion and net income of $1.36 billion over the trailing twelve months, while generating $2.94 billion in EBITDA, which highlights a distinct gap between top-line sales and bottom-line profit due to significant operating expenses and cost of goods sold inherent in delivering clinical services. The generation of $2.22 billion in free cash flow underscores a robust ability to convert earnings into liquidity, providing the financial flexibility necessary to fund R&D partnerships, acquire smaller competitors, or weather periods of reduced revenue without compromising solvency. Margins reveal the company's efficiency structure, with a gross margin of 33.3%, an operating margin of 15.2%, and a profit margin of 8.3%, indicating that while the business generates strong revenue, substantial costs related to personnel and technology are required to realize the final profit. On the balance sheet, the company holds $2.14 billion in cash against total debt of $16.31 billion, resulting in a debt-to-equity ratio of 245.93% that signals a highly leveraged capital structure reliant on consistent cash flow generation to service obligations. Liquidity is constrained by a current ratio of 0.75, suggesting that the company's current assets fall short of covering its current liabilities, which is common for capital-intensive service firms but requires careful management of working capital cycles. Return metrics show a Return on Equity of 21.4% and a Return on Assets of 5.1%, revealing that management generates significant returns for shareholders relative to equity invested, though the return on assets is moderated by the high level of debt financing used to scale the business.
밸류에이션 평가
Valuation multiples for IQVIA reflect market expectations for future earnings expansion, with a trailing P/E ratio of 21.55 compared to a forward P/E of 12.01, implying that the market anticipates a significant acceleration in earnings growth that would justify a lower multiple in the future. The price-to-book ratio stands at 4.41, indicating that the stock trades at a substantial premium over its book value, which suggests investors are pricing in intangible assets such as proprietary data sets, brand reputation, and future growth options rather than just tangible capital. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.76 and an EV/EBITDA of 14.62, suggesting that the company is valued on a revenue basis that is relatively low for a high-growth tech-enabled firm, yet the enterprise multiple reflects the debt burden included in the enterprise value. Price action over the last year shows a 52-week high of $247.05 and a 52-week low of $134.65, placing the current trading price in a range that reflects recent volatility and potential correction from peak valuations. The stock exhibits a beta of 1.39, meaning it is expected to be 39% more volatile than the broader market, which adds a layer of risk for risk-averse investors seeking stability within the healthcare sector.
Growth & Income
Revenue growth stands at 10.3% year-over-year while earnings growth reaches 23.6% year-over-year, indicating that earnings are expanding significantly faster than revenue, likely driven by margin expansion, pricing power, or improved operational efficiency rather than sheer volume increases. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its net income to reinvest in organic growth, strategic acquisitions, or debt reduction rather than distributing cash to shareholders. This reinvestment strategy is typical for companies in the growth phase of their lifecycle, prioritizing capital allocation toward expanding market share in the diagnostics and research space over immediate income generation for investors. Overall, the growth and income profile is characterized by double-digit revenue expansion coupled with accelerating earnings growth, supported by a retention policy that forgoes dividends to fuel long-term value creation through continued investment in clinical research capabilities and technological infrastructure.